No Data
No Data
Express News | BridgeBio: Attribute-Cm Study Shows 42% Cut in Composite ACM and Recurrent Cvh Events at 30 Months Observed With Acoramidis Treatment Vs Placebo
BMO Capital Maintains BridgeBio Pharma(BBIO.US) With Hold Rating, Maintains Target Price $37
Sector Update: Health Care Stocks Steady Premarket Tuesday
Express News | BridgeBio Pharma Inc - Propel 3 Phase 3 Study Enrollment to Complete by Year-End
BridgeBio Pharma Says FDA Has Granted Breakthrough Therapy Designation To Oral Infigratinib Under Development For Children With Achondroplasia
BridgeBio Announces Infigratinib Is the First Ever Investigational Therapeutic Option for Achondroplasia to Be Awarded Breakthrough Therapy Designation by the FDA
No Data
No Data